News
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies. The collaboration aims to develop...
Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion BOSTON--Kelonia Therapeutics, Inc., a biotech company...
Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
BOSTON, Mass., May 9, 2025 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the...
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
BOSTON, Mass., May 2, 2024 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming...
Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma
– Preclinical data supports potential for iGPS® particles to provide off-the-shelf in vivo CAR-T Cell therapies without need for lymphodepleting chemotherapy – BOSTON, Mass., April 2, 2024 - Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
– World-renowned leaders in cell therapy, drug discovery and development join Kelonia as it moves toward early clinical development of in vivo CAR-T cell therapies – BOSTON, Mass., March 28, 2024 - Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
- Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON, Mass., February 15, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D., “Kelonia”)...
Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of All Multiple Myeloma Patients
Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of All Multiple Myeloma Patients Preclinical data in mice and non-human primates demonstrate...
Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS™ Technology at ASGCT Annual Meeting
Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy Company developing iGPS technology to provide potentially safe, efficacious,...
Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines
In Vivo Gene Delivery Platform Will Dramatically Expand the Benefit and Reach of Genetic Medicines Founded and Led by Leading Experts in Immunology, Oncology, and Cell and Gene Therapy Strategic Collaborations with Leading Industry Partners Enable and Accelerate...